S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

XLO Xilio Therapeutics Inc

0.9722

-0.0028 (-0.29%)

28 Dec 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Xilio Therapeutics Charts.

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Xilio Therapeutics Charts.

Xilio Therapeutics Inc News

Form 8-K - Current report
Thursday 19 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Thursday 19 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Monday 16 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 4 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Friday 8 November 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Friday 8 November 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Friday 4 October 2024 (3 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 3 October 2024 (3 months ago) • Edgar (US Regulatory)

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 3 October 2024 (3 months ago) • GlobeNewswire Inc.

More Xilio Therapeutics Inc News Articles

Societe Generale Effekten

IT0005616534 20250602 34

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions